アトピー性皮膚炎治療薬の世界市場予測および分析（～2024）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 14
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 19
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 22
3.2 Symptoms 26
4 Epidemiology 28
4.1 Disease Background 28
4.2 Risk Factors and Comorbidities 28
4.3 Global Trends 29
4.3.1 US 30
4.3.2 France 30
4.3.3 Germany 31
4.3.4 Italy 31
4.3.5 Spain 31
4.3.6 UK 32
4.3.7 Japan 32
4.3.8 China 32
4.3.9 India 33
4.4 Forecast Methodology 33
4.4.1 Sources Used 36
4.4.2 Sources Not Used 41
4.4.3 Forecast Assumptions and Methods 41
4.5 Epidemiological Forecast for Atopic Dermatitis (2014-2024) 42
4.5.1 One-Year Total Prevalent Cases of Atopic Dermatitis 42
4.5.2 Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis 44
4.5.3 Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis 45
4.5.4 Age-Standardized One-Year Total Prevalence of Atopic Dermatitis 47
4.5.5 One-Year Total Prevalent Cases of Atopic Dermatitis by Severity 48
4.6 Discussion 50
4.6.1 Epidemiological Forecast Insight 50
4.6.2 Limitations of the Analysis 50
4.6.3 Strengths of the Analysis 51
5 Disease Management 52
5.1 Diagnosis and Treatment Overview 52
5.1.1 Diagnosis 52
5.1.2 Treatment Guidelines 54
5.1.3 Leading Prescribed Drugs for the Treatment of RA 56
5.1.4 Clinical Practice 58
5.2 US 59
5.3 5EU 64
5.4 Japan 71
6 Competitive Assessment 74
6.1 Overview 74
6.2 Strategic Competitor Assessment 75
6.3 Product Profiles – Major Brands 76
6.3.1 Protopic (tacrolimus) 76
6.3.2 Elidel 84
6.3.3 Cyclosporine (numerous generic names) 89
6.3.4 Other Therapeutic Drug Classes Used in Atopic Dermatitis 94
6.4 Product Profiles – Off-Label Therapies 96
6.4.1 Xolair (omalizumab) 96
6.4.2 Actimmune (interferon gamma-1b) 101
7 Opportunity and Unmet Need 106
7.1 Overview 106
7.1.1 A Systemic Drug for Severe Recalcitrant Patients 107
7.1.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach 110
7.1.3 A Drug that Effectively Controls Patients’ Pruritus 114
7.1.4 Further Research into the Pathophysiology of Atopic Dermatitis 116
7.1.5 A Drug that Induces Disease Remission 119
7.1.6 Improved Quality of Life for Both Patients and their Carers 120
8 Pipeline Assessment 123
8.1 Overview 123
8.2 Clinical Trial Mapping 124
8.2.1 Clinical Trials by Therapy Type 124
8.3 Promising Drugs in Clinical Development 125
8.3.1 Dupilumab (SAR231893/ REGN668) 128
8.3.2 AN2728 142
8.3.3 Other Drugs in Development 154
9 Current and Future Players 156
9.1 Overview 156
9.2 Trends in Corporate Strategy 158
9.3 Company Profiles 159
9.3.1 Astellas 159
9.3.2 Meda 162
9.3.3 Sanofi/Regeneron/Boehringer Ingelheim 164
9.3.4 Anacor 166
10 Market Outlook 169
10.1 Global Markets 169
10.1.1 Forecast 169
10.1.2 Global Drivers and Barriers 173
10.2 US 178
10.2.1 Forecast 178
10.2.2 Key Events 182
10.2.3 Drivers and Barriers 182
10.3 5EU 184
10.3.1 Forecast 184
10.3.2 Key Events 189
10.3.3 Drivers and Barriers 189
10.4 Japan 194
10.4.1 Forecast 194
10.4.2 Key Events 197
10.4.3 Drivers and Barriers 197
11 Appendix 200
11.1 Bibliography 200
11.2 Abbreviations 213
11.3 Methodology 215
11.4 Forecasting Methodology 215
11.4.1 Diagnosed Atopic Dermatitis Patients 215
11.4.2 Percent Drug-treated Patients 216
11.4.3 Drugs Included in Each Therapeutic Class 216
11.4.4 Launch and Patent Expiry Dates 216
11.4.5 General Pricing Assumptions 217
11.4.6 Individual Drug Assumptions 218
11.4.7 Generic Erosion 220
11.4.8 Pricing of Pipeline Agents 220
11.5 Physicians and Specialists Included in this Study 221
11.6 Primary Research – Prescriber Survey 223
11.7 About the Authors 224
11.7.1 Author 224
11.7.2 Reviewer 224
11.7.3 Epidemiologist 225
11.7.4 Global Director of Therapy Analysis and Epidemiology 225
11.7.5 Global Head of Healthcare 226
11.8 About GlobalData 227
11.9 Disclaimer 227